GnT-III Inhibitors

Swainsonine is an indolizidine alkaloid known as an inhibitor of Golgi alpha-mannosidase II, which is involved in the trimming of the mannose residues on N-linked glycoproteins. As GnT-III is responsible for the addition of a bisecting N-acetylglucosamine to N-glycans in the Golgi apparatus, the inhibition of mannose trimming by swainsonine can prevent the proper substrate formation that GnT-III requires for its activity.

Kifunensine is a mannosidase I inhibitor that interferes with the early glycan processing in the ER, preventing the formation of the high mannose-type glycans that are substrates for further modification by GnT-III in the Golgi apparatus.

This compound serves as a competitive inhibitor for various glycosyltransferases and could compete with the donor substrate of GnT-III, UDP-GlcNAc, thus inhibiting its glycosyltransferase activity.

Castanospermine is a glucosidase inhibitor that can inhibit the processing of N-linked oligosaccharides in the ER. By doing so, it may indirectly inhibit GnT-III by disrupting the early steps of glycan maturation required for GnT-III's later action in the Golgi.

Deoxynojirimycin is an iminosugar that acts as an α-glucosidase inhibitor. By inhibiting glucosidases that process N-glycans in the ER, it could indirectly inhibit GnT-III by preventing the formation of substrates that GnT-III modifies in the Golgi.

Deoxymannojirimycin is an inhibitor of mannosidase I. By preventing the trimming of mannose residues on N-glycans, it can indirectly inhibit GnT-III by averting the formation of suitable substrates for GnT-III activity.

Celgosivir is an α-glucosidase I inhibitor, which may impede the initial glycan processing in the ER, affecting the subsequent action of GnT-III by limiting the availability of mature glycans for its enzymatic activity in the Golgi.

Brefeldin A disrupts Golgi structure and function by inhibiting protein transport from the ER to the Golgi. This disruption could indirectly inhibit GnT-III by preventing the access of glycan substrates to the Golgi, where GnT-III exerts its enzymatic function.

Tunicamycin inhibits N-linked glycosylation by blocking the formation of the lipid-linked oligosaccharide precursor. This inhibition prevents the initial step of N-glycosylation, thereby indirectly inhibiting GnT-III by obviating the formation of N-glycans that GnT-III would modify.